Published in TB and Outbreaks Week, April 27th, 2004
"Edema factor (EF), a key virulence factor in anthrax pathogenesis, has calmodulin (CaM)-activated adenylyl cyclase activity. We have found that adefovir dipivoxil, a drug approved to treat chronic infection of hepatitis B virus, effectively inhibits EF-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages," researchers writing in the Proceedings of the National Academy of Sciences USA report.
Y.Q. Shen and colleagues, University Chicago, Ben May Institute Cancer Research found, "Adefovir diphosphate (IPMEApp), the active...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week